GlycoMimetics Reports Program Updates and Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Glycomimetics (GLYC) PT Lowered to $15 at Jefferies; Reiterates Buy
November 9, 2017 8:55 AM ESTJefferies lowered its price target on Glycomimetics (NASDAQ: GLYC) to $15.00 (from $16.00) while maintaining a Buy rating following the company's 3Q earnings report and pipeline update. GLYC reported GAAP EPS of ($0.24) vs consensus of ($0.28), reflecting lower R&D costs than previously... More
